We would like to thank all participants for taking part in the International Conference „Clinical Genetics of Cancer 2024”.

Projekt Międzynarodowa Konferencji „Genetyka Kliniczna Nowotworów 2024” został dofinansowany ze środków budżetu państwa, przyznanych przez Ministra Nauki w ramach programu „Doskonała Nauka II” (projekt nr KONF/SP/0086/2024/02).

We invite you to participate in the Scientific Conference next year.

Abstracts:

1. Tumour Mutational Burden using the TSO-500: How does it help in patient management (R. Scott, Newcastle)
2. Germline genetic of rare cancers (K. Hemminki, Pilsen, Heidelberg)
3. Germline variants in cancer patients with personal and family history of colorectal cancer: an update (A. Försti, Heidelberg)
4. Incidences of colorectal adenomas and cancers under colonoscopy surveillance suggest an accelerated “Big Bang” pathway to CRC in three of the four Lynch syndromes (P. Moller, Oslo)
5. Association between Blood Levels of Selenium, Zinc and Copper and Survival in Colorectal Cancer Patients with Lynch Syndrome (M. Marciniak, Szczecin)
6. Spectrum of the mutations predisposing to occurrence of colorectal polyposis (A. Pławski, Poznań)
7. Treatment of BRCA1-positive ER+ breast cancer: An observational study (S. Narod, Toronto)
8. Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: lower rates for 5-years post chemotherapy (G. Evans, Manchester)
9. Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 mutations (J. Kotsopoulos, Toronto)
10. Ovarian cancer prevention in the general and in the high risk population (R. Fruscio, Milan)
11. Polygenic inheritance and the risk of ovarian carcinoma (E. Grzybowska, Gliwice)
12. Bilateral Mastectomy and Breast Cancer Mortality (V. Giannakeas, Toronto)
13. Prostate cancer genetics in practice now and in the future (J. McHugh, London)
14. Personalized nanodiagnostics of prostate cancer. A proposal for repositioning genetic testing on the timeline of the diagnostic and therapeutic process (B. Kałużewski, Łódź)
15. Serum Copper, Zinc, and Copper/Zinc Ratio Levels as Biomarkers of Survival Among Prostate Cancer Patients (S. Pietrzak, Szczecin)
16. MRI Surveillance and Breast Cancer Mortality in Women with BRCA1 and BRCA2 Sequence Variations (J. Gronwald, Szczecin)
17. Pilot results of elements blood levels of computational analyses in diagnosis of cancer risk among BRCA1 carriers (Z. Suszyński, Koszalin)
18. Blood Elements Levels and Cancer Risk in BRCA1 Mutation Carriers: A Prospective Study (M. Matuszczak, Szczecin)
19. Blood cells of BRCA1 mutation and epimutation carriers appear to acquire specific epigenetic signatures (K. Sokołowska, Szczecin)
20. Blood and urinary arsenic levels are associated with methylation of promoters of genes involved in molecular processes related to arsenic toxicity (K. Sokołowska, Szczecin)
21. BRCA1/2 population screening pilot in Latvia. Lessons to learn (A. Irmejs, Riga)
22. SELINA – optimization of Se and As blood levels is decreasing cancer risk in females from families with predisposition to hereditary breast cancers (J. Lubiński, Szczecin)
23. The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (M. Szwiec, Zielona Góra)
24. Association of constitutional BRCA1 methylation with genetic alterations in promoter region and genome-wide methylation signature (K. Prajzendanc, Szczecin)
25. Results of DMSA long-term supplementation in lowering lead blood level (E. Siwiec, Szczecin)
26. Genomic instability, microenvironment and telomere homeostasis in solid malignancies (P. Vodička, Pilsen)
27. MCR1 as prognostic marker in malignant melanoma (T. Dębniak, Szczecin)
28. Methylome-based Pan Cancer Classifier (MePCC) – pan-cancer classification based on methylomics data (J. Bińkowski, Szczecin)
29. Evaluation of serum selenium concentration and polymorphisms of genes responsible for selenium metabolism in women with endometrial cancer (M. Jankowska, Rzeszów)
30. Axiom_PolMut1 – polish custom genetic test for cancer predisposition and other genetically determined diseases (K. Białkowska, Szczecin)
31. Blood and Serum Se and Zn Levels and 10-Year Survival of Patients after a Diagnosis of Kidney Cancer (E. Złowocka-Perłowska, Szczecin)
32. Are current Polish guidelines for prophylactic mastectomy sufficient? (A. Stachowski, Szczecin)
33. (R. Mądry, Poznań)
34. Population sereening for founder mutations of high cancer risk in Poland (C. Cybulski, Szczecin)
35. PALB2 mutation female carriers registry (A. Stachowski, Szczecin)
36. Determining homologous recombination deficiency (HRD) in comprehensive genomic profiling (CGP) (A. Tysarowski, Warszawa)
37. Rozliczanie badań genetycznych w wybranych nowotworach – możliwości i bariery (A. Tysarowski, Warszawa)
38. Organizacje pacjenckie: Osobista i medyczna podróż pacjentki z mutacjami BRCA2 i CHECK2 (S. Pogorzelska – Ogólnopolskie Stowarzyszenie Wspierania Rodzin z Predyspozycjami do Nowotworów Dziedzicznych) on-line OmeaReh rehabilitacja chorych na raka piersi w warunkach domowych  (A. Woźniak-Marciniak – Fundacja OmeaLife Rak piersi nie ogranicza)
39. Meeting of Section of Clinical Genetics of Cancer of Polish Society of Human Genetics National Programme of Diagnostics and Surveillance in Families with Increased Predisposition to Cancers – analysis of current arrangements – (O. Haus, Bydgoszcz) – (M. Stawicka, Zielona Góra) – (A. Prusaczyk, Siedlce)
40. Certyfikacja umiejętności z genetyki klinicznej nowotworów dla lekarzy i nie-lekarzy – doradców genetycznych (T. Dębniak, J. Lubiński, Szczecin)